{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T21:34:17Z","timestamp":1779399257481,"version":"3.53.1"},"reference-count":24,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Integrating shared decision making between patients and physicians and incorporating their values and preferences in the development of clinical practice guidelines (CPGs) is of critical importance to optimize CPG implementation and treatment adherence. This applies to many debilitating diseases, including hypercalcemia of malignancy (HCM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Evaluate patient and physician values, preferences, and attitudes to better inform CPGs to treat HCM in adults.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We followed a mixed-methods approach. We conducted a systematic review using 5 databases to identify studies reporting on patient and physician values, costs and resources, feasibility, acceptability, and equity regarding HCM treatment. We also gathered data from different countries on the cost of multiple treatment modalities. We collected data on outcome prioritization from the CPG Working Group. Similarly, we collected data from patients with HCM regarding outcome prioritization and administered a questionnaire to evaluate their attitudes and perceptions toward treatment as well as treatment acceptability and feasibility.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the systematic review, we included 2 cross-sectional surveys conducted on the same population of physicians who agreed that treating HCM alleviates symptoms and improves quality of life; however, harms and benefits should be thoroughly considered when deciding on the duration of treatment. We also included 2 studies on cost showing that intravenous (IV) bisphosphonate is more cost-effective than a combination of IV bisphosphonate and calcitonin and administration of IV zoledronic acid at home is more cost-effective than other IV bisphosphonates. The cost of zoledronic acid, denosumab, and cinacalcet varied widely among countries and types (brand vs generic). Both the CPG Working Group and patients with HCM agreed that the most important outcomes when deciding on treatment were survival and resolution of HCM, but there was some variability in the ratings for other outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Using mixed methods, CPG developers can obtain meaningful information regarding evidence to decision criteria. In the case of HCM CPGs, this approach has provided the required contextual information and supported the development of evidence-based recommendations.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgac630","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T07:44:46Z","timestamp":1671695086000},"page":"563-584","source":"Crossref","is-referenced-by-count":7,"title":["Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7841-3986","authenticated-orcid":false,"given":"Aya","family":"Bassatne","sequence":"first","affiliation":[{"name":"Scholars in HeAlth Research Program (SHARP), American University of Beirut , Beirut , Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad H","family":"Murad","sequence":"additional","affiliation":[{"name":"Robert D. and Patricia E. Kern Center for the Science of Health Care Deliver, Mayo Clinic , Rochester, MN 55905 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Piggott","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, Ontario , Canada"},{"name":"Department of Family Medicine, Queens University , Kingston, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T","family":"Drake","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Kogod Center of Aging, Mayo Clinic College of Medicine , Rochester, MN 55905 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Rahme","sequence":"additional","affiliation":[{"name":"Calcium Metabolism and Osteoporosis Program, Division of Endocrinology and Metabolism, Department of Internal Medicine, American University of Beirut Medical Center , Beirut , Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2076-5858","authenticated-orcid":false,"given":"Ghada","family":"El-Hajj Fuleihan","sequence":"additional","affiliation":[{"name":"Scholars in HeAlth Research Program (SHARP), American University of Beirut , Beirut , Lebanon"},{"name":"Calcium Metabolism and Osteoporosis Program, Division of Endocrinology and Metabolism, Department of Internal Medicine, American University of Beirut Medical Center , Beirut , Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"issue":"1","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.healthpol.2015.10.005","article-title":"How to integrate research evidence on patient preferences in pharmaceutical coverage decisions and clinical practice guidelines: a qualitative study among Dutch stakeholders","volume":"120","author":"Utens","year":"2016","journal-title":"Health Policy"},{"issue":"3","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/intqhc\/mzw020","article-title":"Added value of involving patients in the first step of multidisciplinary guideline development: a qualitative interview study among infertile patients","volume":"28","author":"Den Breejen","year":"2016","journal-title":"Int J Quality Health Care"},{"issue":"1","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13012-018-0745-6","article-title":"Impact of patient involvement on clinical practice guideline development: a parallel group study","volume":"13","author":"Armstrong","year":"2018","journal-title":"Implement Sci"},{"issue":"7","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00198-019-04913-y","article-title":"Evidence of patient beliefs, values, and preferences is not provided in osteoporosis clinical practice guidelines","volume":"30","author":"Sale","year":"2019","journal-title":"Osteoporos Int"},{"issue":"5","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1210\/jc.2019-00193","article-title":"Women's values and preferences regarding osteoporosis treatments: a systematic review","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"i2016","DOI":"10.1136\/bmj.i2016","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"issue":"19","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1001\/jama.288.19.2469","article-title":"Patient self-management of chronic disease in primary care","volume":"288","author":"Bodenheimer","year":"2002","journal-title":"JAMA"},{"key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"a1864","DOI":"10.1136\/bmj.a1864","article-title":"Patients' preferences within randomised trials: systematic review and patient level meta-analysis","volume":"337","author":"Preference Collaborative Review Group","year":"2008","journal-title":"BMJ"},{"issue":"10","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"e051141","DOI":"10.1136\/bmjopen-2021-051141","article-title":"Values and other decisional factors regarding treatment of hypercalcaemia of malignancy: a systematic review protocol","volume":"11","author":"Bassatne","year":"2021","journal-title":"BMJ Open"},{"key":"2023021518394959800_","year":"2021"},{"key":"2023021518394959800_","volume-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Shea","year":"2000"},{"issue":"9","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/jpm.2015.0460","article-title":"Interspecialty differences in Physicians' attitudes, beliefs, and reasons for withdrawing or withholding hypercalcemia treatment in terminally ill patients","volume":"19","author":"Mori","year":"2016","journal-title":"J Palliat Med"},{"issue":"1","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00520-014-2355-4","article-title":"Physicians' attitude toward recurrent hypercalcemia in terminally ill cancer patients","volume":"23","author":"Shimada","year":"2015","journal-title":"Support Care Cancer"},{"issue":"2","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3747\/co.v17i2.507","article-title":"Feasibility of administering zoledronic acid in palliative patients being cared for in the community: results of a pilot study","volume":"17","author":"Marr","year":"2010","journal-title":"Curr Oncol"},{"issue":"3","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1060028020957048","article-title":"Bisphosphonate versus bisphosphonate and calcitonin for the treatment of moderate to severe hypercalcemia of malignancy","volume":"55","author":"Khan","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"5","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/106002809603000514","article-title":"Acute management of cancer-related hypercalcemia","volume":"30","author":"Chisholm","year":"1996","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1742-1241.2011.02831.x","article-title":"Differences in physician attitudes towards patient-centredness: across four medical specialties","volume":"66","author":"Chan","year":"2012","journal-title":"Int J Clin Pract"},{"issue":"17","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.3390\/ijerph17176393","article-title":"Do Physicians' attitudes towards patient-centered communication promote Physicians' intention and behavior of involving patients in medical decisions?","volume":"17","author":"Wang","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"2023021518394959800_","article-title":"What is patient-centered care?","volume":"3","author":"Catalyst NEJM","year":"2017","journal-title":"NEJM Catalyst"},{"issue":"12","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1745-7599.2008.00360.x","article-title":"Patient-centered care and adherence: definitions and applications to improve outcomes","volume":"20","author":"Robinson","year":"2008","journal-title":"J Am Acad Nurse Pract"},{"issue":"6","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3322\/caac.21245","article-title":"Implementing and evaluating shared decision making in oncology practice","volume":"64","author":"Kane","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"e1S","DOI":"10.1378\/chest.11-2290","article-title":"Patient values and preferences in decision making for antithrombotic therapy: a systematic review: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"MacLean","year":"2012","journal-title":"Chest"},{"key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"E151","DOI":"10.5888\/pcd17.200244","article-title":"Cost-related nonadherence and mortality in patients with chronic disease: a multiyear investigation, National Health Interview Survey, 2000\u20132014","volume":"17","author":"Van Alsten","year":"2020","journal-title":"Prev Chronic Dis"},{"issue":"4","key":"2023021518394959800_","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1503\/cmaj.121637","article-title":"Addressing cost-related barriers to prescription drug use in Canada","volume":"186","author":"Tang","year":"2014","journal-title":"CMAJ"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac630\/48869198\/dgac630.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/3\/563\/49201227\/dgac630.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/3\/563\/49201227\/dgac630.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T19:23:02Z","timestamp":1679167382000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/3\/563\/6916874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,12,21]]},"published-print":{"date-parts":[[2023,2,15]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac630","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,12,21]]}}}